Filing Flows › Tenaya Therapeutics (TNYA) › Q3 2026 › vs Q2 2026
Tenaya Therapeutics (TNYA) Q3 2026 vs Q2 2026 (quarter over quarter)
Tenaya Therapeutics's revenue rose $587K (+53%) from $1.1M in Q2 2026 to $1.7M in Q3 2026.
Tenaya Therapeutics, Q3 2026: revenue $1.7M, net loss $18.9M, operating cash flow −$17.7M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.7M | $1.1M | $587K | +53% |
| Other income, net | $634K | $695K | −$61K | -9% |
| Net loss | $18.9M | $43.4M | −$24.5M | -56% |
| Costs & expenses | $21.3M | $45.2M | −$23.9M | -53% |
| Operating costs | $21.3M | $45.2M | −$23.9M | -53% |
| Research & development | $14.9M | $16.6M | −$1.7M | -10% |
| General & admin | $5.6M | $5.4M | $242K | +4% |
| Other operating costs | $755K | $23.2M | −$22.4M | -97% |
| Operating cash sources | $19.8M | $7.0M | $12.8M | +184% |
| Depreciation & amortization | $394K | $1.7M | −$1.3M | -77% |
| Share-based compensation | $1.7M | $1.7M | −$22K | -1% |
| Cash used in operations | $17.7M | $3.6M | $14.1M | +398% |
| Net loss absorbed | $18.9M | $43.4M | −$24.5M | -56% |
| Working capital & other | $819K | −$36.4M | $37.3M | — |
Questions
How much did Tenaya Therapeutics's revenue grow quarter over quarter in Q3 2026?
Tenaya Therapeutics's revenue rose $587K (+53%) from $1.1M in Q2 2026 to $1.7M in Q3 2026.